Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplet Therapy Followed by Radium-223 Maintenance in High-Volume mHSPC
2026-525550-11-00Phase 2Authorised
- Sponsor
- GUARD Consortium
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa), sponsored by GUARD Consortium. Primary endpoint: Treatment compliance. Planned start Aug 2026; status: authorised.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2026-525550-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525550-11-00.